UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 

  REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 

For the month of March, 2015
 

 
Commission File Number: 001-36582

Auris Medical Holding AG
(Exact name of registrant as specified in its charter)

Bahnhofstrasse 21
6300 Zug, Switzerland
(Address of principal executive office)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F
X
 
Form 40-F
 


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes
   
No
X


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes
   
No
X
 

 



 
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
   
Auris Medical Holding AG
 
 
     
By:
/s/ Thomas Meyer
       
Name:
Thomas Meyer
       
Title:
Chief Executive Officer

Date: March 30, 2015
 

 
 

 

EXHIBIT INDEX

Exhibit Number
Description
99.1
Press Release dated March 30, 2015
99.2
Letter to Shareholders dated March 30, 2015
99.3
Proxy Form for the 2015 Annual General Meeting
99.4
2014 Statutory Annual Report
99.5
Compensation Report

 
Exhibit 99.1
 

 
Auris Medical News Release

Auris Medical to Propose Election of Two New Board Members at Forthcoming Annual General Meeting
 
Zug, Switzerland, March 30, 2015 Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that its Board of Directors will propose the election of two new members of the Board of Directors at its forthcoming Annual General Meeting:
 
Berndt Modig, CPA, MBA
 
Berndt A. Modig was the Chief Financial Officer of Prosensa Holding N.V., a company dedicated to the development of treatments of neuromuscular and neurodegenerative disorders, such as Duchenne Muscular Dystrophy, from 2010 up to its recent sale to Biomarin. Prior to that, he was the CFO of Jerini AG, another publicly-traded biotechnology company, and has held other various management positions in industry, finance and private equity groups. Berndt began his professional career in the auditing practice of Price Waterhouse. He is a member of the Board of Directors and the Audit Committee of Affimed N.V. Berndt is a Certified Public Accountant and received an M.B.A. from INSEAD.
 
Calvin Roberts, MD
 
Calvin W. Roberts, MD, is Chief Medical Officer at Bausch + Lomb and Senior Vice President and Chief Medical Officer, Eye Care, of Valeant Pharmaceuticals. He joined Bausch + Lomb in 2011. Dr. Roberts is a specialist in cataract and refractive surgery and has been a pioneer in the use of ophthalmic non-steroidals. Since 1982, he has been a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University; in addition, he maintained a private ophthalmology practice in New York City between 1998 and 2008. Dr. Roberts is the author of over 50 peer-reviewed articles. He has been a member of the Board of Directors and the Audit Committee of Alimera Sciences, Inc., since it was founded in 2003.
 
Alain Munoz, MD, has decided not to stand for re-election at the 2015 Annual General Meeting following more than 7 years of dedicated and outstanding service. Hence, the size of the Board of Directors will increase from 6 to 7 members, subject to the election of the proposed two new members.
 
“We are delighted to propose the election of Berndt Modig and Calvin Roberts to our Board,” commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “Berndt has built an excellent track record as a financial executive in the biotechnology industry and is intimately familiar with the aspects of drug development in new therapeutic indications. With a successful career in ophthalmology, first as a key opinion leader, and then as a member of the executive team of one of the industry’s leading companies, Cal has significant product development and marketing experience in a field with many similarities to otology.  Additionally, I’d like to thank Alain for his important contributions to our Board over the years.”

 
Auris Medical Holding AG · Bahnhofstrasse 21 · CH-6300 Zug · Tel. +41 41 729 71 94 · www.aurismedical.com
 
 

 
 
The Annual General Meeting will take place in Zug, Switzerland, on April 22, 2015 and begin at 10.30 a.m. local time. The agenda for the meeting, as well as the financial statements of Auris Medical Holding AG for the 2014 financial year, are available on the Company’s website www.aurismedical.com in the Investor Relations section.
 
About Auris Medical
 
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
 
Forward-looking Statements
 
This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or Auris Medical’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials of Auris Medical’s product candidates, the clinical utility of Auris Medical’s product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical’s intellectual property position and Auris Medical’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical’s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in Auris Medical’s prospectus relating to its Registration Statement on Form F-1, as amended, and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
 
Contact: Dr. Sven Zimmermann, CFO, +41 41 729 71 94, investors@aurismedical.com
Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, matthew@lifesciadvisors.com


 
Exhibit 99.2
 

 
Zug, March 30, 2015
 
 
To the shareholders of Auris Medical Holding AG
 
Notice of Annual General Meeting
 
Date: Wednesday, April 22, 2015, 10.30 a.m. (doors open 10.00 a.m.)
 
Place: Theater Casino Zug, Artherstrasse 2-4, 6300 Zug, Switzerland
 
Agenda
 
1.  
Approval of the Annual Report of Auris Medical Holding AG, the financial statements of Auris Medical Holding AG and the Group Consolidated Financial Statements for the 2014 financial year
 
The Board of Directors proposes approval.
 
2.  
Discharge from liability of the members of the Board of Directors and the Executive Committee
 
The Board of Directors proposes discharge from liability for its members and for the members of the Executive Committee for the 2014 financial year.
 
3.  
Appropriation of the financial result
 
Balance brought forward
CHF 34,193,525
Net income 2014
CHF 34‘193‘520
Net income as per balance sheet
CHF 34,193,525
 
The Board of Directors proposes to carry forward the balance of CHF 34,193,525.
 
4.  
Votes on compensation for the members of the Board of Directors and the Executive Committee
 
In accordance with Article 21 of the articles of association the General Meeting shall approve prospectively the maximum aggregate amount of compensation for the Board of Directors for the following term of office up to the following Annual General Meeting as well as the maximum aggregate amount of compensation for the Executive Committee for the 2016 financial year. Further information on the proposals for compensation as well as the Compensation Report 2014 is available electronically in the Investor Relations section of the Company’s website www.aurismedical.com.
 

 
1/4

 
 
 
4.1.
Aggregate amount of compensation for the Board of Directors for the period from the 2015 Annual General Meeting to the 2016 Annual General Meeting
 
The Board of Directors proposes to approve a maximum aggregate compensation of CHF 600,000  (gross amount) for the members of the Board of Directors for the period from the 2015 Annual General Meeting to the 2016 Annual General Meeting.
 
 
4.2
Aggregate amount of compensation for the members of the Executive Committee for the 2016 financial year
 
The Board of Directors proposes to approve a maximum aggregate compensation of CHF 2,000,000 (gross amount) for the members of the Executive Committee for the 2016 financial year.
 
5.  
Re-election of the Chairman and members of the Board of Directors, Election to the Board of Directors
 
Dr. Alain Munoz has decided not to stand for re-election at the 2015 Annual General Meeting. The Board of Directors sincerely thanks Alain Munoz for his many years of distinguished service and for his dedication and commitment to Auris Medical.
 
The Board of Directors proposes the re-election of Thomas Meyer, PhD (as member and Chairman of the Board of Directors), Prof. Wolfgang Arnold, MD, James Healy, MD, PhD, Oliver Kubli, Antoine Papiernik as well as the election of Berndt Modig, CPA, MBA and Calvin Roberts, MD, as members of the Board of Directors, each for a term of office until the end of the next Annual General Meeting.
 
 
5.1
Re-election of Thomas Meyer, PhD, as member and Chairman of the Board of Directors
 
 
5.2
Re-election of Prof. Wolfgang Arnold, MD as member
 
 
5.3
Re-election of James Healy, MD, PhD as member
 
 
5.4
Re-election of Oliver Kubli as member
 
 
5.5
Re-election of Antoine Papiernik as member
 
 
5.6
Election of Berndt Modig as member
 
Berndt A. Modig is a Certified Public Accountant and has an MBA from INSEAD. He was the Chief Financial Officer of Prosensa Holding N.V., a company dedicated to the development of treatments of neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy, from 2010 up to its recent sale to Biomarin. Prior to that, he was the CFO of Jerini AG, another publicly listed biotechnology company, and held various management positions in industry, finance and private equity groups. He started his professional career in the auditing practice of Price Waterhouse. Berndt Modig is a member of the Board of Directors and the Audit Committee of Affimed N.V. He meets the independence criteria set forth by the Nasdaq Listing Standards and the Board of Directors.
 
 
5.7
Election of Calvin Roberts, MD as member
 
Calvin W. Roberts, MD, is Chief Medical Officer at Bausch + Lomb and Senior Vice President and Chief Medical Officer, Eye Care of Valeant Pharmaceuticals. He joined Bausch + Lomb in 2011. Dr. Roberts is a specialist in cataract and refractive surgery and has been a pioneer in the use of ophthalmic non-steroidals. Since 1982 he has been a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University; in addition, he had a private ophthalmology practice in New York City between 1998 and 2008. He is the author of over 50 peer-reviewed articles. Dr. Roberts has been a member of the Board of Directors and the Audit Committee of Alimera
 

 
2/4

 
 
Sciences, Inc., since it was founded in 2003. He meets the independence criteria set forth by the Nasdaq Listing Standards and the Board of Directors.
 
6.  
Re-elections and election to the Compensation Committee
 
The Board of Directors proposes the re-election of Antoine Papiernik and Prof. Wolfgang Arnold, MD, and the election of James Healy, MD, PhD as members of the Compensation Committee, each for a term of office until the end of the next Annual General Meeting. The Board of Directors intends to designate Antoine Papiernik, as Chairman of the Compensation Committee again, subject to his re-election as a member of the Compensation Committee.
 
7.  
Re-election of the Auditors
 
The Board of Directors proposes the re-election of Deloitte AG as statutory Auditors of Auris Medical Holding AG for the 2015 financial year.
 
8.  
Re-election of the Independent Proxy
 
The Board of Directors proposes the re-election of Sandro G. Tobler, Attorney at Law and public notary, Zug, as Independent Proxy of Auris Medical Holding AG for a term of office until the end of the next Annual General Meeting.
 
For the Board of Directors
 
The Chairman:
 
 
Thomas Meyer, PhD
 

(The original German text is binding)

Enclosures (in the mailing to shareholders recorded in the Companys share registered as of March 30, 2015):
·  
Admission ticket for the 2015 Annual General Meeting
·  
Proxy form for the 2015 Annual General Meeting
·  
Annual Report 2014
·  
Audit Report
·  
Compensation Report
·  
Form 20-F


 
3/4

 
 
Organizational Notes

 
Annual Report
The Annual Report of Auris Medical Holding AG (including the financial statements of Auris Medical Holding AG and the Group Consolidated Financial Statements for the 2014 financial year), the Compensation Report as well as the statutory auditor’s reports on each one are available for inspection by shareholders at the registered office of the Company. In addition, the Annual Report and the Compensation Report are available in the Investor Relations section of the Company’s website at www.aurismedical.com.

Tickets of admission
Tickets and voting materials will be sent to all shareholders recorded in the Company’s share register as of March 30, 2015 or may be requested at any time before April 20, 2015 by shareholders with proof of ownership. Requests for tickets of admission that are received after April 20, 2015 cannot be taken into account. Voting rights may only be exercised for shares recorded in the share register on the Record Date (April 20, 2015) or for which proof of ownership has been provided and accepted on the Record Date.

Appointment of proxy
A shareholder may appoint another shareholder with the right to vote, a third party, the Independent Proxy (Sandro G. Tobler, lic.iur., Attorney at Law and notary public, BKS Advokatur Notariat, Alpenstrasse 2, 6300 Zug, Switzerland), or his legal representative to act as proxy to represent his or her shares at the Annual General Meeting. Proxies may only be appointed for one Annual General Meeting. Shareholders may use the enclosed form to appoint the Independent Proxy and give voting instructions. Please send the form together with the Admission Ticket directly to the Independent Proxy.

Cocktail
Following the Annual General Meeting a cocktail will be offered.

In case of questions relating to the Annual General Meeting please contact:

Auris Medical Holding AG
Sven Zimmermann, PhD, CFO
Bahnhofstrasse 21
6300 Zug
Phone +41 41 729 71 94
Investors@aurismedical.com
 
 
4/4


t
Exhibit 99.3
 

 
Sandro G. Tobler, lic.iur.
Attorney at Law and public notary
BKS Advokatur Notariat
Alpenstrasse 2
CH-6300 Zug
 
Annual General Meeting of Auris Medical Holding AG
Wednesday, April 22, 2015, 10:30 a.m. (doors open at 10:00 a.m.)
Theater Casino Zug, Artherstrasse 2-4, 6300 Zug, Switzerland
 
Power of Attorney
 
I/we do not attend the Annual General Meeting in person and herewith grant power of  attorney to the Independent Proxy with the following instructions:
1.
General instruction for the proposals of the Board of Directors:
 
Approval of the proposals of the Board of Directors
 
Disapproval of the proposals of the Board of Directors
 
Abstention
2.
General instruction for motions or matters that have not been notified with the agenda:
 
Approval of the proposals of the Board of Directors
 
Disapproval of the proposals of the Board of Directors
 
Abstention
3.
Individual instructions for proposals on the agenda:
(please tick the desired individual instruction on the backside)
Note on power of attorney to the Independent Proxy:
Please send your admission ticket together with this power of attorney form directly to the Independent Proxy. If you grant power of attorney to him without voting instructions, he will abstain from voting your shares.
     
Name
 
Address
 
Date
 
Signature
 
 
Date
 
Signature*
 
*A second signature is required in case of joint signature powers of a legal entity.
 
 
 
 

 
 
3. Individual instructions to the Independent Proxy
 
Please provide below individual instructions to the extent that they differ from the general instruction. The individual instructions below take precedence over the general instruction.
 
Agenda Item
Approve
Disapprove
Abstention
1.
Approval of the Annual Report of Auris Medical Holding AG, the financial statements of Auris Medical Holding AG and the Group Consolidated Financial Statements for the 2014 financial year
2.
Discharge from liability of the members of the Board of Directors and the Executive Committee
3.
Appropriation of the financial result
4.
Approval of the compensation for the members of the Board of Directors and the Executive Committee
4.1
Aggregate amount of compensation for the Board of Directors
4.2
Aggregate amount of compensation for the members of the Executive Committee
5.
Re-election of the Chairman and members of the Board of Directors, Election to the Board of Directors
5.1
Re-election of Thomas Meyer, PhD, as member and Chairman of the Board of Directors
5.2
Re-election of Prof. Wolfgang Arnold, MD as member
5.3
Re-election of James Healy, MD, PhD, as member
5.4
Re-election of Oliver Kubli as member
5.5
Re-election of Antoine Papiernik as member
5.6
Election of Berndt Modig as member
5.7
Election of Calvin Roberts, MD, as member
6.
Re-elections and election to the Compensation Committee
6.1
Re-election of Antoine Papiernik as member
6.2
Re-election of Prof. Wolfgang Arnold, MD, as member
6.3
Election of James Healy, MD, PhD, as member
7.
Re-election of the Auditors, Deloitte AG
8.
Re-election of the Independent Proxy, Sandro G. Tobler
 


 
Exhibit 99.4
 

 
AURIS MEDICAL HOLDING AG,
ZUG
 
(FORMERLY: AURIS MEDICAL AG)
 
Financial Statements for the Year Ended
December 31, 2014 and Report of
the Statutory Auditor

 
 
 
 

 
AURIS MEDICAL HOLDING AG
Report of the Statutory Auditor
for the Year Ended
December 31, 2014
Report of the Statutory Auditor

To the General Meeting of
AURIS MEDICAL HOLDING AG, ZUG (formerly: Auris Medical AG)

Report of the Statutory Auditor on the Financial Statements

As Statutory Auditor, we have audited the accompanying financial statements of Auris Medical Holding AG, which comprise the statement of financial position as of December 31, 2014, and the statements of profit or loss and notes for the year then ended.

Board of Directors’ Responsibility
The Board of Directors is responsible for the preparation of these financial statements in accordance with the requirements of Swiss law and the Company’s articles of incorporation. This responsibility includes designing, implementing and maintaining an internal control system relevant to the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The Board of Directors is further responsible for selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.

Auditor’s Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Swiss law and Swiss Auditing Standards. Those standards require that we plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers the internal control system relevant to the entity’s preparation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control system. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of accounting estimates made, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the financial statements for the year ended December 31, 2014 comply with Swiss law and the Company’s articles of incorporation.

 
 
 

 
AURIS MEDICAL HOLDING AG
Report of the Statutory Auditor
for the Year Ended
December 31, 2014
 
Other Matter
The financial statements of the Company as of and for the year ended December 31, 2014 were audited by another auditor whose report, dated March 18, 2014, expressed an unqualified opinion on those financial statements.
 
Report on Other Legal Requirements
 
We confirm that we meet the legal requirements on licensing according to the Auditor Oversight Act (“AOA”) and independence in accordance with Article 728 of the Swiss Code of Obligations (“CO”) and Article 11, AOA, and that there are no circumstances incompatible with our independence.

In accordance with Article 728a, paragraph 1, item 3, CO, and Swiss Auditing Standard 890, we confirm that an internal control system exists, which has been designed for the preparation of financial statements according to the instructions of the Board of Directors.

We recommend that the financial statements submitted to you be approved.


Deloitte AG

 
Martin Welser
James D. Horiguchi
Licensed Audit Expert
 
Auditor in Charge
 
 
 
Zurich, March 30, 2015
 
Enclosures
- Financial statements
 
 
 
 

 
Exhibit 99.4
 

AURIS MEDICAL HOLDING AG, ZUG (Formerly: Auris Medical AG)
 
STATEMENTS OF PROFIT OR LOSS FOR THE YEARS ENDED DECEMBER 31, 2014,
AND  2013
           
           
 
Notes
 
2014
 
2013
     
in CHF
 
in CHF
           
Net Revenue
   
-
 
-
Research and Development Expenses
   
-13'985
 
-21'026'842
Development expenses
3
 
-
 
-20'926'140
Patent expenses
   
-13'985
 
-100'702
General and Administration Expenses
   
-3'555'399
 
-1'334'470
IPO expenses
   
-1'980'422
 
-
Public listing expenses
   
-547'322
 
-
Professional fees
   
-810'904
 
-694'252
Administration expense
4
 
-216'751
 
-640'218
Financial Income/Expense
   
3'569'384
 
-44'221
Net foreign exchange gain/(loss)
   
3'409'148
 
-115'924
Interest income
   
161'608
 
74'036
Bank charges
   
-1'372
 
-2'333
Loss before direct taxes
   
-
 
-22'405'533
Direct taxes
   
-
 
-
Loss for the Year
   
-
 
-22'405'533
           

 
 
1

 
AURIS MEDICAL HOLDING AG, ZUG (Formerly: Auris Medical AG)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED
DECEMBER 31, 2014 AND 2013

AURIS MEDICAL HOLDING AG, ZUG (Formerly: Auris Medical AG)
 
STATEMENTS OF FINANCIAL POSITION AS OF DECEMBER 31, 2014 AND 2013
 
Notes
 
2014
 
2013
     
in CHF
 
in CHF
ASSETS
         
           
Current assets
   
     56'009'498
 
     24'561'925
Cash and cash equivalents
   
     55'784'353
 
     23'854'004
Other short-term receivables
   
45'274
 
524'784
Trade receivables
   
45'274
 
          524'784
Prepaid expenses
   
179'871
 
183'137
           
Non-current assets
   
17'527'618
 
175'459
Other long-term receivables
   
14'927'461
 
-
Intercompany loans, subordinated
6
 
14'927'461
 
-
Fixed assets
5
 
-
 
175'302
Investments in subsidiaries
7
 
2'600'157
 
157
TOTAL ASSETS
   
     73'537'116
 
     24'737'384
           
LIABILITIES
         
Current liabilities
   
870'152
 
16'718'442
Short-term payables
   
265'735
 
935'712
Trade payables
   
151'595
 
935'712
Intercompany receivables
   
114'140
 
-
Other short-term payables
   
-
 
13'771'628
Trade payables
   
-
 
1'630
Shareholder
   
-
 
22
Convertible loan (with shareholders)
   
-
 
13'769'976
Accrued expenses
   
604'417
 
2'011'102
Equity
13
 
72'666'964
 
8'018'942
Share capital
10 – 13
 
11'604'156
 
6'487'130
Share premium
   
95'256'333
 
35'725'337
Accumulated loss
14
 
34'193'525
 
34'193'525
Loss for the year
   
-
 
-22'405'533
Loss carryforward
   
-34'193'525
 
-11'787'992
TOTAL LIABILITIES AND EQUITY
   
73'537'116
 
24'737'384

 
 
2

 
AURIS MEDICAL HOLDING AG, ZUG (Formerly: Auris Medical AG)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED
DECEMBER 31, 2014 AND 2013

1.  
GENERAL INFORMATION
On April 22, 2014, the Company changed its name from Auris Medical AG to Auris Medical Holding AG (“the Company”) and transferred the operational business to the newly incorporated subsidiary, Auris Medical AG, which is now the main operating subsidiary (Asset transfer agreement). Therefore, the financial statements are not fully comparable between 2014 and 2013.
 
INFORMATON ON AVERAGE FULL-TIME POSITIONS
 
The annual average in 2014 is below 10 employees (2013: below 10 employees)
 
REGISTERED NAME, LEGAL FORM AND DOMICILE
 
Auris Medical Holding AG, Limited Liability Company, Bahnhofstrasse 21, 6300 Zug
 
INFORMATION ON PREVIOUS YEAR’S BALANCES
 
Prior year balances are reclassified to conform with the current year presentation, which is in accordance with the new Swiss financial reporting law.
 
2.  
KEY ACCOUNTING AND VALUATION PRINCIPLES
 
The financial statements have been prepared in accordance with the regulations of Swiss financial reporting law.
 
ESTIMATES AND ASSUMPTIONS MADE BY MANAGEMENT
Financial reporting under the Swiss Code of Obligations (“CO”) requires certain estimates and assumptions to be made by management. These are made continuously and are based on past experience and other factors (e.g. anticipation of future results, which seem appropriate under the circumstances). The results subsequently achieved may deviate from these estimates.

FOREIGN CURRENCY ITEMS
The currency in which Auris Medical Holding AG operates is Swiss Francs (CHF). Transactions in foreign currencies are converted into the currency in which the Company operates (CHF) at the exchange rate on the day the transactions takes places.
-  
Current assets and liabilities in foreign curencies are converted into the currency in which Company operates at the exchange rate on the balance sheet date. Any profits or losses resulting from the exchange rates applied are recorded in the profit and loss account.
 
-  
Non-current assets and liabilities at historical costs are converted at the foreign currency exchange rate at the time of the transaction. Any foreign currency exchange profits are deferred in the balance sheet. Foreign currency exchange losses, on the other hand, are recorded in the profit and loss account.


 
3

 
AURIS MEDICAL HOLDING AG, ZUG (Formerly: Auris Medical AG)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED
DECEMBER 31, 2014 AND 2013
 
 
3.    IMPAIRMENT OF INTANGIBLE ASSETS

in CHF
2014
2013
Capitalized R&D expenses
6,730,336
Total
6,730,336
 
The impairment of intangible assets in 2013 is related to R&D expenses previously capitalized, therefore the impairment was grouped into the R&D expense financial statement line.
 
4.   ADMINISTRATION EXPENSES
 
in CHF
2014
2013
Personnel
105,685
373,546
Travel
52,543
77,616
Capital tax
35,081
42,090
Other administration
23,442
146,966
Total
216,751
640,218

5.   DEPRECIATION OF FIXED ASSETS
 
in CHF
2014
2013
Fixed assets
37,912
Total
37,912
 
6.   INTERCOMPANY LOAN AND SUBORDINATION AGREEMENT

On December 31, 2014, Auris Medical Holding AG entered into loan and subordination agreements with its wholly owned subsidiaries, Auris Medical AG and Otolanum AG. Under the terms of the loan agreement, the lender, Auris Medical Holding AG, grants the borrowers, Auris Medical AG and Otolanum AG, a credit facility in a maximum amount of CHF 45,000,000 and CHF 1,000,000, respectively, to be used for general business and operational purposes. The borrowers may draw down the facility in full or in part. As of December 31, 2014, Auris Medical AG and Otolanum AG had drawn down loans under the facility of CHF 14,471,061 and CHF 456,400, respectively. The Company expects that the subsidiaries will repay these loans and therefore no impairment is required.

 
4

 
AURIS MEDICAL HOLDING AG, ZUG (Formerly: Auris Medical AG)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED
DECEMBER 31, 2014 AND 2013


The interest rate on the loans is equivalent to the rate published by the Swiss Federal Tax Authorities (ESTV) in its circular on recognized interest rates (Rundschreiben Steuerlich Anerkannte Zinssätze). Interest is charged on the portion of the facility which is drawn down.

All claims under the loan agreements are subordinated to all other existing and future claims against those subsidiaries. In the event of insolvency proceedings (Art. 175, Art. 192, Swiss Debt Enforcement and Insolvency Law) and in the event of a composition agreement with assignment of assets (Art. 317, Swiss Debt Enforcement and Insolvency Law), the Company waives its claims to the extent necessary that the claims of all other creditors are covered in full by the proceeds of the liquidation of the subsidiaries.

7.   INVESTMENTS IN SUBSIDIARIES
 
Subsidiary
Participation
Share Capital
Purpose of the Company
Auris Medical AG, Basel
100%
CHF 2,500,000
Research and Development
Otolanum AG, Zug
100%
CHF 100,000
Intellectual Property Management
Auris Medical Inc, Chicago
100%
USD 15,000
Research and Development
Auris Medical Ltd, Dublin
100%
EUR 100
Administration
 
8.   CONVERTIBLE LOAN
 
On December 9, 2013, the Company issued non-interest bearing convertible loans to two shareholders with a nominal value of CHF 13,769,976 and a maximum term of 12 months. Between January 10 and January 17, 2014, the lenders and the Company had the right to convert the loans into new registered Series C preferred shares with a nominal value of CHF 0.40 each for CHF 5.28 per share. On January 27, 2014, the loans were converted into new Series C preferred shares with a nominal value of CHF 0.40 each for CHF 5.28 per share. The Company issued 2,607,950 Series C preferred shares upon the conversion.
 
9.   COMMITMENTS AND CONTINGENT LIABILITIES
 
in CHF
   
Operating lease commitments
   
Within one year
6,000
91,572
Between one and five years
122,096
Total
6,000
213,668
 
 
 
5

 
AURIS MEDICAL HOLDING AG, ZUG (Formerly: Auris Medical AG)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED
DECEMBER 31, 2014 AND 2013
 

10.   SHARE CAPITAL - IPO on NASDAQ Global Market

On August 6, 2014, the underwriters for the Company’s IPO subscribed to purchase 9,400,000 shares at USD 6.00 per share yielding gross proceeds (before underwriting fees and IPO costs) of USD 56.4 million. On August 13, 2014, the underwriters exercised their overallotment option for 713,235 shares of the Company, resulting in gross proceeds of USD 4.3 million. All 18,753,175 preferred shares outstanding at the time of the IPO were converted into common shares on a 1:1 basis.
 
11.   AUTHORIZED SHARE CAPITAL
 
Prior to the IPO, the Company’s authorized share capital consisted of common shares and preferred shares. Preferred shares (Series A, B, and C) had the same voting rights and dividend rights as common shares but enjoyed a liquidation preference. All preferred shares were converted into common shares upon the IPO of the Company. In August 2014, the shareholders approved an extension and increase of the authorized capital of the Company. The Board is authorized to increase the share capital at any time until June 30, 2016 by the maximum amount of CHF 3,314,706 by issuing not more than 8,286,765 registered shares with a nominal value of CHF 0.40 each. The shares will have to be fully paid-in.
 
12.   CONDITIONAL SHARE CAPITAL
 
The share capital may be increased by the issuance of up to 1,500,000 fully paid-in registered common shares with a nominal value of CHF 0.40 per share and to the maximum amount of CHF 600,000 in execution of subscription rights, which may be granted to employees, members of the Board of Directors, as well as key service providers. As of December 31, 2014, the conditional share capital for these purposes amounts to CHF 581,823.60 or 1,444,119 common shares with a nominal value of CHF 0.40 each, following the exercise of 55,881 stock options in 2014 after the IPO. A further 15,500 stock options had been exercised in 2014 prior to the IPO out of the preceding conditional share capital that was superseded by amended articles of association in connection with the IPO.
 
The Company’s share capital may be further increased by the issuance of up to 5,000,000 fully paid registered common shares with a nominal value of CHF 0.40 per share and to the maximum amount of CHF 2,000,000 in execution of conversion rights in connection with any warrants and convertible bonds of the Company.
 

 
6

 
AURIS MEDICAL HOLDING AG, ZUG (Formerly: Auris Medical AG)
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED
DECEMBER 31, 2014 AND 2013
 
 
13.   CHANGES IN EQUITY ACCOUNTS
 
The following table presents activity related to our equity accounts during 2014 and 2013:
 
 
Attributable to owners of the company
 
Share
capital
Share
premium
Accumulated
Deficit
Total
Equity
As of January 1, 2013
      4,632,580
      13,341,942
  -11,787,992
     6,186,530
Net loss
                     -
                       -
  -22,405,533
 -22,405,533
Issue of ordinary shares
      1,854,550
      22,625,510
                    -
  24,480,060
Share issuance costs
                     -
           -242,115
                    -
       -242,115
Balance at December 31, 2013
      6,487,130
      35,725,337
  -34,193,525
     8,018,942
As of January 1, 2014
      6,487,130
      35,725,337
  -34,193,525
     8,018,942
Capital increase from IPO
      4,045,294
      47,261,446
                    -
  51,306,740
Conversion of convertible loans
      1,043,180
      12,726,796
                    -
  13,769,976
Share issuance costs
                     -
           -682,860
                    -
       -682,860
Share options exercised (see Note 14)
            28,552
            225,614
                    -
        254,166
Balance at December 31, 2014
    11,604,156
      95,256,333
  -34,193,525
  72,666,964
 
14.   LOSS CARRYFORWARDS
 
Tax loss carryforwards may be used by our operating company Auris Medical AG, Basel, in accordance with applicable tax laws.
 
15.   SIGNIFICANT SHAREHOLDERS
 
 
Shares Beneficially Owned
Shareholder
Number
Percent
Above 5% Shareholders
   
Thomas Meyer, CEO & Chairman.
6,742,500
23.2%
Sofinnova Venture
   Partners VIII, L.P.
5,818,175
20.1%
Sofinnova Capital VII FCPR
5,384,450
18.6%
Entities affiliated with ZKB
2,169,625
7.5%
Entities affiliated with Idinvest Partners
2,065,233
7.1%
Clifton Park Capital Management, LLC
1,666,667
5.7%
FMR LLC
1,666,667
5.7%
 
The percentage of common shares beneficially owned is based on 29,010,391 common shares issued and outstanding as of December 31, 2014. As of December 2013, the Company was non-public.
 
16.    INFORMATION ON ALLOCATION OF SHARES AND OPTIONS TO EXECUTIVE OFFICERS, DIRECTORS AND EMPLOYEES

The following table presents information on the allocation of shares and options to Executive Officers, Directors and Employees in accordance with Article 959c, paragraph 2, figure 11, CO:
  Shares Options
2013
Number
CHF
Number
CHF
Allocated to Executive Officers
and Directors
-  
-  
100,000
272,746
Allocated to Employees
-  
-  
26,250
79,452
Total
   
126,250
352,198
     
 
Shares
Options
2014
Number
CHF
Number
CHF
Allocated to Executive Officers
and Directors
20,881
90,415
143,760
349,416
Allocated to Employees
-  
-  
53,000
102,630
Total
 
   
196,760
452,046
 
 
 
7

 
 
 
17.      BENEFICIAL OWNERSHIP OF EXECUTIVE OFFICERS AND DIRECTORS

The table below presents beneficial ownership of Executive Officers and Directors, including affiliated entities, if applicable, in accordance with Article 663c, CO:
 
Board Members and Executive Committee Members 1) 2)
 
No. of Shares
 
No. of Options
2014
2014
Thomas Meyer, Ph.D.
Chairman of the Board
Chief Executive Officer
6,742,500
110,000
Oliver Kubli
Board Member / Head of Audit Committee
non executive
2,188,375
20,315
Wolfgang Arnold, M.D.
Board Member
non executive
12,500
32,815
Alain Munoz, M.D.
Board Member
non executive
12,500
32,815
James I. Healy, M.D., Ph.D.
Board Member
non executive
5,818,175
14,065
Antoine Papiernik
Board Member
non executive
5,384,450
6,250
Bettina Stubinski, M.D.
Chief Medical Officer
25,862
43,750
Sven Zimmermann, Ph.D.
Chief Financial Officer
29,019
27,500
     
1) Includes holdings of "companies closely linked” to members of the Board or Executive Committee (see further details in item 7 A. of the 20-F).
2) As of December 2013 the Company was non-public.
 
18.      OTHER DISCLOSURES
 
Information on compensation of Executive Officers and Directors in accordance with Article 663b bis, CO, is included in the Company’s separate Compensation Report.
 
19.      SUBSEQUENT EVENTS
 
There are no events subsequent to December 31, 2014 that require adjustment to or disclosure in these financial statements.
 

8

 
Exhibit 99.5
 

 
AURIS MEDICAL
HOLDING AG,
ZUG
 
(FORMERLY: AURIS MEDICAL AG)
 
Compensation Report for the year ended
December 31, 2014 in Accordance with the
Ordinance against Excessive Compensation in Stock
Exchange Listed Companies (Ordinance) and
Report of the Statutory Auditor
 
 
 

 
 

 
 
Report of the Statutory Auditor

To the General Meeting of
AURIS MEDICAL HOLDING AG, ZUG (formerly: Auris Medical AG)
 
We have audited the accompanying Compensation Report of Auris Medical Holding AG for the year ended December 31, 2014.
 
Responsibility of the Board of Directors
The Board of Directors is responsible for the preparation and overall fair presentation of the Compensation Report in accordance with Swiss law and the Ordinance Against Excessive Compensation in Stock Exchange Listed Companies (Ordinance). The Board of Directors is also responsible for designing the compensation system and defining individual remuneration packages.
 
Auditor's Responsibility
Our responsibility is to express an opinion on the accompanying Compensation Report. We conducted our audit in accordance with Swiss Auditing Standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Compensation Report complies with Swiss law and Articles 14 – 16 of the Ordinance.
 
An audit involves performing procedures to obtain audit evidence on the disclosures made in the Compensation Report with regard to compensation, loans and credits in accordance with Articles 14 – 16 of the Ordinance. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatements in the Compensation Report, whether due to fraud or error. An audit also includes evaluating the reasonableness of the methods applied to value components of compensation, as well as assessing the overall presentation of the Compensation Report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.


 
 

 
AURIS MEDICAL HOLDING AG
Report of the Statutory Auditor in relation to the
Compensation Report as of December 31, 2014


 
Opinion
In our opinion, the Compensation Report for the year ended December 31, 2014 of Auris Medical Holding AG complies with Swiss law and Articles 14 – 16 of the Ordinance.


Deloitte AG
 

 

Martin Welser
James D. Horiguchi
Licensed audit expert
 
Auditor in charge
 
 
Zurich, March 30, 2015
MWE/JDH/jva

 
Enclosures
- Compensation Report 2014
 

 
 
 

 
AURIS MEDICAL HOLDING AG
Compensation Report for the Year ended December 31, 2014
 
This compensation report has been prepared in accordance with the Federal Ordinance Against Excessive Compensation in Stock Exchange Listed Companies (“Ordinance”), effective January 1, 2014.
 
Compensation for the Board of Directors
The compensation package for Board members consists of different elements, as indicated below. The respective amounts for the period from the 2014 Annual Shareholder Meeting up to the Company's IPO on August 8, 2014 and the period since the IPO up to the Company's Annual General Meeting in 2015 were as follows:
 
 
 
LC
CHF
Chairman of the Board of Directors1
-
-
Board meeting fee up to IPO2
CHF 1,750
CHF 1,750
Fixed compensation since IPO (per annum)
USD 20,000
CHF 19,296
Board meeting fee since IPO3
USD 2,500
CHF 2,412
Committee Chairman meeting fee since IPO4
USD 2,000
CHF 1,929
Committee member meeting fee since IPO5
USD 1,000
CHF 964

 
1
Since the office of Chairman of the Board is held by the Company’s Chief Executive Officer, no separate remuneration is paid.
2
Paid only to independent members of the Board of Directors
3
USD 1500 / CHF 1447 for participation via teleconference
4
USD 1000 / CHF 964 for participation via teleconference
5
USD 500 / CHF 482 for participation via teleconference

 
The total compensation of the members of the Board of Directors in 2014 is outlined below:
 
In CHF
Cash compensation
Social contributions and other fringe benefits
Stock options6
Total
Thomas Meyer, PhD, Chairman1
-
-
-
-
James Healy, MD, PhD, Vice-Chairman2
11,426
714
13,398
25,538
Wolfgang Arnold, MD3
16,374
937
13,398
30,709
Oliver Kubli, CFA4
13,838
2,201
13,398
29,437
Alain Munoz, MD2
12,873
2,105
13,398
28,377
Antoine Papiernik, MBA5
27,056
-
-
27,056
Total
81,567
5,957
53,539
141,118

 
 
1

 
AURIS MEDICAL HOLDING AG
Compensation Report for the Year ended December 31, 2014
 
 
1
Disclosed under Compensation for the Members of the Executive Committee
2
Member of the Audit Committee
3
Member of the Compensation Committee
4
Chairman of the Audit Committee
5
Chairman of the Compensation Committee. Stock options paid in cash. Mr Papiernik’s compensation was paid in its entirety to Sofinnova Partners.
6
Based on the grant date fair value of stock options granted in 2014 using the Black-Scholes model

The total compensation of the members of the Board of Directors in 2013 is outlined below:

In CHF
Cash compensation
Social contributions and other fringe benefits
Stock options2
Total
Thomas Meyer, PhD, Chairman1
-
-
-
-
James Healy, MD, PhD
-
-
18,917
18,917
Wolfgang Arnold, MD
8,750
-
18,917
27,667
Oliver Kubli, CFA, Vice-Chairman
-
-
18,917
18,917
Alain Munoz, MD
-
-
18,917
18,917
Antoine Papiernik, MBA
-
-
18,917
18,917
Total
8,750
-
94,586
103,336
 
1
Disclosed under Compensation for the Members of the Executive Committee
2
Based on the grant date fair value of stock options granted in 2013 using the Black-Scholes model
 
 
Compensation for the Members of the Executive Committee
 
The total compensation and the highest individual compensation of the members of the Executive Committee in 2014 are outlined below:
 
in CHF
Cash Compensation, fixed
Compensation, variable
Social contributions and other fringe benefits
Stock Options1
Total
Thomas Meyer, PhD, Chief Executive Officer
360,000
-
52,963
173,460
586,423
Total Executive Committee compensation
916,250
92,567
144,000
295,823
1,356,073

1
Based on the grant date fair value of stock options granted in 2014 using the Black-Scholes model

 
 
2

 
AURIS MEDICAL HOLDING AG
Compensation Report for the Year ended December 31, 2014
 
 
The total compensation and the highest individual compensation of the members of the Company’s Management in 2013 are outlined below:
 
in CHF
Cash Compensation, fixed
Compensation, variable
Social contributions and other fringe benefits
Stock Options3
Total
Thomas Meyer, PhD, Chief Executive Officer1
248,000
-
-
121,408
369,408
Total Management compensation2
327,382
-
8,870
178,160
514,412


1
The Chief Executive Officer was compensated in 2013 by means of a management agreement between Auris Medical AG and Altamira Pharma GmbH, a company fully owned by the CEO
2
The amount includes the compensation for the Chief Medical Officer who joined the company in September 2013
3
Based on the grant date fair value of stock options granted in 2013 using the Black-Scholes model

 
 
3